Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
MargheRITA (Remote Intelligence for Therapeutic Adherence)
- Status
- COMPLETED
- Phase
- NA
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Plasma-free Replacement in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- NA
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE3
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE2
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
- Status
- RECRUITING
- Phase
- N/A
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
- Status
- COMPLETED
- Phase
- N/A
Financial Difficulty in Patients With Blood Cancer
- Status
- COMPLETED
- Phase
- N/A
Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.
- Status
- RECRUITING
- Phase
- N/A
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Status
- RECRUITING
- Phase
- PHASE4
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2